Tetrahydropyridopyrimidine compound or salt thereof

A method for inhibiting androgen activity, comprising:

• administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof,
• wherein, in the formula (I),
• X is a halogen atom or a halogeno-C1-3 alkyl group;
• R is a C6-14 aryl group which is substituted with R1 and is simultaneously substituted or unsubstituted with R2, or a 5- or 6-membered heteroaryl group which is substituted with R1 and is simultaneously substituted or unsubstituted with R2;
• R1 is a hydrogen atom, a phenyl group, a hydroxy-C1-6 alkyl group, a hydroxy-C3-7 cycloalkyl group, a C1-6 alkoxy group which is substituted or unsubstituted with Ra, a C3-7 cycloalkylaminosulfonyl group, a 3- to 7-membered monocyclic heterocycloalkylsulfonyl group, a halogeno-C1-3 alkoxycarbonylamino group, a halogeno-C1-3 alkylcarbonylamino group, a 3- to 7-membered monocyclic heterocycloalkanecarbonyl group substituted with a hydroxy-C1-6 alkyl group, or —(CH2)n—C(═O)—NHRf;
• R2 is a hydrogen atom, a halogen atom, or a halogeno-C1-3 alkyl group;
• Ra is a C1-6 alkylpyrazolyl group, a triazolyl group, a tetrazolyl group, or a C1-6 alkylsulfonylpiperazinyl group;
• Rf is a halogeno-C1-3 alkyl group, a hydroxy-C1-6 alkyl group, a hydroxy-C3-7 cycloalkyl group, a hydroxy-C3-7 cycloalkyl-C1-6 alkyl group, or a C1-6 alkyl group substituted with Rfa;
• Rfa is a C1-6 alkylpyrazolyl group, a halogeno-C1-3 alkylthiazolyl group, an oxadiazolyl group, or a halogeno-C1-3 alkyloxadiazolyl group;
• and
• n is an integer of from 0 to 3.